Poll

POLL: Will you use biosimilars in your ophthalmic practice?

Author(s):

Sheryl Stevenson

Let us know if you will plan to use biosimilars in your daily practice. The poll will be open until October 10, 2022.

Will you use biosimilars in your ophthalmic practice?

Yes, I plan to use biosimilars in my practice
No, I do not plan to use biosimilars in my practice

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Related Content
European Union flags outside a parliament building. Concept image for European Commission approval and European Medicines Agency regulatory decision on aflibercept biosimilar Mynzepli. Image credit: ©artjazz – stock.adobe.com
August 21st 2025

European Commission approves aflibercept biosimilar Mynzepli

3 Things You Should Know About the GA Pipeline
August 21st 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: SeeWhatMatters)
August 21st 2025

Q&A: AEVR's executive director on #SeeWhatMatters and safeguarding the National Eye Institute

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 21st 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
August 21st 2025

FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease

An eye on how patients perceive their retinal diseases
August 21st 2025

An eye on how patients perceive their retinal diseases

© 2025 MJH Life Sciences

All rights reserved.